AI Article Synopsis
- Time in tight range (TITR) is a new important metric for measuring normal blood sugar levels, particularly for people with type 1 diabetes (T1D).
- A study evaluated the performance of the advanced hybrid closed-loop (AHCL) Minimed™ 780G system in 42 adults with T1D over a year.
- The results showed that after just 14 days, the AHCL system significantly improved TITR and other glucose metrics, maintaining effective glycemic control for the full 12 months.
Article Abstract
Introduction: Time in tight range (TITR) is an emerging and valuable metric for assessing normoglycemia. The latest advancement in automated insulin delivery (AID) systems, the advanced hybrid closed-loop (AHCL) systems, are particularly noteworthy for managing type 1 diabetes (T1D) and enhancing glycemic control.
Methods: In a real-world clinical setting, we carried out a retrospective evaluation of TITR in 42 adult subjects with T1D using the AHCL Minimed™ 780G system over a 12-month period.
Results: Within just 14 days of activating the automatic mode, the AHCL Minimed™ 780G system showed rapid improvement in TITR, and in the other continuous glucose monitoring (CGM) metrics. This improvement persisted over 12 months, achieving the proposed 45-50% range for effective glycemic control.
Conclusion: The AHCL Minimed™ 780G system significantly enhances TITR, demonstrating continuous improvement throughout a 12-month follow-up period.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561210 | PMC |
| http://dx.doi.org/10.1007/s13300-024-01656-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improving glycaemic control in children under 3 years using MiniMed™ 780G in SmartGuard™ AHCL with diluted insulin: a case series report.
Acta Diabetol
December 2024
Department of Endocrinology, Sydney Children's Hospital, Randwick, NSW, Australia.
Real-world glycaemic outcomes in children and young people on advanced hybrid closed-loop therapy: A population-based study in Western Australia.
J Paediatr Child Health
January 2025
Department of Endocrinology and Diabetes, Perth Children's Hospital, Perth, Western Australia, Australia.
Aims: To evaluate real-world glycaemic outcomes in children with type 1 diabetes (T1D) commencing advanced hybrid closed loop therapy (AHCL) and to explore these outcomes based on the cohort's clinical and socioeconomic characteristics.
Methods: A single-centre, population-based retrospective study in children commencing AHCL (Smart Guard, Control IQ, CamAPS) with minimum 70% data from two-weeks CGM pre-AHCL was conducted between December 2021 and June 2023 in Western Australia. CGM metrics (time in range (TIR) 3.
Parental perspectives following the implementation of advanced hybrid closed-loop therapy in children and adolescents with type 1 diabetes and elevated glycaemia.
Diabet Med
November 2024
Department of Women's and Children's Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Aims: To identify from a parental perspective facilitators and barriers of effective implementation of advanced hybrid closed-loop (AHCL) therapy in children and adolescents with type 1 diabetes (T1D) with elevated glycaemia.
Methods: Semi-structured interviews were conducted with parents of participants while in a post-trial extension phase of the CO-PILOT randomized controlled trial. The Capability, Opportunity, Motivation, Behaviour Model and Theoretical Domain Framework informed the interviews and framework analysis.
Comparison of the night-time effectiveness in achieving glycemic targets in adults with type 1 diabetes of three advanced hybryd closed-loop systems.
Acta Diabetol
November 2024
Unit of Endocrine Diseases and Diabetology, Department of Medicine, ASST Papa Giovanni XXIII, Piazza OMS, 1, 24127, Bergamo, Italy.
Article Synopsis
- Advanced hybrid closed loop (AHCL) systems are the latest insulin therapy for adults with type 1 diabetes, aiming to assess their effectiveness during nighttime hours.
- A study of 55 adults evaluated three AHCL systems (Minimed 780G, Tandem t:slim X2 with Control-IQ, and DBLG1) based on continuous glucose monitoring over 14 nights.
- All systems met glycemic targets, but the Tandem t:slim X2 with Control-IQ system achieved a significantly higher percentage of time in range (TIR), suggesting better overall performance.
Comparing quality of life in traditional face-to-face visits with a hybrid approach of telemedicine with in-person follow-ups in recent users of advanced closed-loop systems: a randomized controlled clinical trial in patients with type 1 diabetes.
Ther Adv Endocrinol Metab
October 2024
Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Background: Our objective was to assess the effect of a hybrid telemedicine approach, in conjunction with face-to-face follow-up, on the quality of life in recent users of an advanced hybrid closed-loop (AHCL) system.
Methods: A 1-year open randomized (1:1) clinical trial (ClinicalTrials.gov ID NCT04900636).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!